This infographic showcases how Generative AI is driving smarter drug innovation across the pharmaceutical industry. It highlights Eularis' expertise in accelerating drug discovery, improving clinical development, strengthening AI governance, and enabling future-ready growth through strategic, trusted, and sustainable AI solutions.
To view Our infographic, Click here...
Write a comment ...
In this episode of AI For Pharma Growth, Dr Andree Bates speaks with Bret Bostwick from Breyer Capital about the rare path from genetics, clinical medicine and drug development into venture capital, and what that perspective reveals about the future of healthcare innovation.
Healthcare is currently experiencing one of its biggest transformations in history, with artificial intelligence in pharma and biotech being the driving force behind this revolution. The impact of this technology spans across the entire healthcare industry from drug discovery to improved patient treatment and care.
In pharma, AI governance sits at the intersection of enterprise technology risk, regulated-process controls, and emerging AI law. The question is no longer just whether a tool is enterprise-approved. It is whether the specific use of that tool is understood, classified, governed, documented, and, where needed, validated for the context in which it is being used.
For many decades the pharmaceutical industry has always struggled with one major issue: the development of drugs takes years of hard work and lots of money to develop a drug, and the majority of attempts fail even before becoming available to patients. However, all these facts have become a norm, “the cost of doing business,” in the industry for many decades.
For most of modern medicine, biological data has been built around population averages: what people like you might experience, rather than what you personally will. In this episode, Dr Andree Bates speaks with Ken Clark, co-founder and CEO of Enigma Genetics, about moving from population models to personal intelligence, and what it could mean for patients, pharma and the future of biological data.
Functional leaders in regulatory affairs, medical affairs, commercial, and market access have now seen enough AI demonstrations to understand what is possible. They have watched an agent draft a literature summary in a few minutes. They have seen AI support medical information triage, assemble competitive landscapes and pre-populate sections of regulatory submissions.
The goal of all medical practitioners has always been precision. However, up till recently, precision in medicine was achieved through larger scans, more accurate imaging, and medicines that were customized for specific issues. The future of precision medicine lies in technology that is very tiny.
Have you ever thought about tiny robots moving inside your body to identify and combat an illness at its source? Although it sounds like something from a science fiction film, nanobots in medicine are actually making a swift transition from study paper pages to actual healthcare. They are also bringing about an incredible change.
In pharma, the biggest deals are increasingly won or lost before a formal process even begins. In this episode, Dr Andree Bates interviews Andrey Doronichev, co-founder and CEO of Bioptic, about the “intelligence gap” in business development, licensing, and corporate strategy, and why many companies are losing opportunities before they even know they’re competing.
The following infographic shows how AI in Life Sciences is helping accelerate research and development through smarter data analytics, faster drug discovery, better clinical development, informed decision-making, and forward-thinking innovations. Eularis assists life sciences companies use AI to gain growth and transformation.
Enrolment isn’t a “soft” operational risk in drug development – it’s the hard constraint that quietly determines whether a promising asset reaches patients on time or bleeds value in limbo. In today’s clinical landscape, recruitment timelines are missed so routinely that it has become the norm rather than the exception, with widely cited analyses indicating that roughly 80% of trials experience delays driven by enrolment.
The life sciences sector is at a really critical crossroad. From pharmaceutical firms dealing with patent cliffs to biopharma groups racing to push new therapies into market, the pressure to innovate has just never been higher. And really, at the middle of all this shift sits artificial intelligence in life sciences — a tool that is changing, in practice, how research gets done, how drug candidates are built and tested, and how healthcare organisations manage sustainable growth.
The future of medical clinical research is kind of being rewritten already — not only in labs, but also in lines of code, machine learning models, and AI-led strategies that are shifting how trials are basically designed, carried out, and delivered. Eularis, a global leader in AI strategy for biopharma and life sciences with over 20 years of experience, sees this change as more than just a distant goal. It’s happening right now, like today.
This infographic on Artificial Intelligence in Pharma and Biotech highlights how AI is transforming drug discovery, clinical research, and patient care. Eularis provides innovative AI-driven solutions that help pharmaceutical and biotech companies improve efficiency, accelerate innovation, and support smarter healthcare decisions
Cell therapies have huge potential, but cost, complexity, and centralised manufacturing have kept many of them confined to last-line use. In this episode, Dr Andree Bates speaks with Armon Sharei, Founder and CEO of Portal Biotechnologies, about what happens when AI meets cell engineering, and why point-of-care delivery could make personalised cell programming more practical, scalable, and safer.
The clinical trial ecosystem – a $90 billion engine driving medical innovation is struggling under the burden of its own complexity. Despite significant advancements in therapeutic science, a substantial portion of trial costs is lost to operational inefficiencies, including prolonged manual data reconciliation, challenges in patient recruitment, and reactive regulatory compliance.
The pharmaceutical industry is experiencing a complete digital transformation while organizations have identified drug regulatory affairs as their critical area for maintaining market competitiveness.The pharma regulatory affairs department, which formerly depended on documentation and compliance checks together with manual processes, has transformed itself into a strategic department that uses modern technologies.
Pharmaceutical companies today demonstrate fast growth because their research work shows them how to develop new products through artificial intelligence applications in life science research. Eularis helps organisations to transform their complex data into practical insights which they use to make better decisions and develop products more quickly and achieve superior results for patients.
AI ethics has moved from theory to urgent necessity, especially as AI systems become embedded in healthcare, business decisions, and society at large. In this episode, Dr Andree Bates is joined by Dr Nadia Morozova, founder of Enriched Insights, to unpack what ethical AI really means in practice, and how organisations can innovate quickly without creating risk, bias, or governance failures.
Write a comment ...